Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2:1 inhibitor/NC stoichiometry

Journal of Molecular Biology

Volumn 425, Issue 11, 2013, Pages 1982-1998

  Goudreau, Nathalie ^a   Hucke, Oliver ^a   Faucher, Anne Marie ^a   Grand Maître, Chantal ^a   Lepage, Olivier ^a   Bonneau, Pierre R ^a   Mason, Stephen W ^a   Titolo, Steve ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

binding studies; drug design; HIV 1 nucleocapsid; NMR spectroscopy; protein ligand structure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GUANOSINE; HUMAN IMMUNODEFICIENCY VIRUS 1 NUCLEOCAPSID PROTEIN INHIBITOR; NUCLEIC ACID BASE; NUCLEOCAPSID PROTEIN; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ABSORPTION SPECTROSCOPY; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN NUCLEIC ACID INTERACTION; STEREOCHEMISTRY; STOICHIOMETRY; STRUCTURE ANALYSIS; VIRUS NUCLEOCAPSID;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84877686314     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2013.02.022     Document Type: Article

References (53)

1. E. De Clercq Antiretroviral drugs Curr. Opin. Pharmacol. 10 2010 507 515
2. H. McManus, C.C. O'Connor, M. Boyd, J. Broom, D. Russell, and K. Watson Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy PLoS One 7 2012 e48839
3. M.W. Tang, and R.W. Shafer HIV-1 antiretroviral resistance scientific principles and clinical applications Drugs 72 2012 e1 e25
4. N. Permpalung, O. Putcharoen, A. Avihingsanon, and K. Ruxrungtham Treatment of HIV infection with once-daily regimens Expert Opin. Pharmacother. 13 2012 2301 2317
5. S. Moreno, J. López Aldeguer, J.R. Arribas, P. Domingo, J.A. Iribarren, and E. Ribera The future of antiretroviral therapy: challenges and needs J. Antimicrob. Chemother. 65 2010 827 835
6. B. Taiwo, C. Hicks, and J. Eron Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1 J. Antimicrob. Chemother. 65 2010 1100 1107
7. W.I. Sundquist, and H.-G. Kräusslich HIV-1 assembly, budding, and maturation Cold Spring Harbor Perspect. Med. 2 2012 a006924
8. B.K. Ganser-Pornillos, M. Yeager, and W.I. Sundquist The structural biology of HIV assembly Curr. Opin. Struct. Biol. 18 2008 203 217
9. P.E. Prevelige Jr. New approaches for antiviral targeting of HIV assembly J. Mol. Biol. 410 2011 634 640
10. A.A. Waheed, and E.O. Freed HIV type-1 Gag as a target for antiviral therapy AIDS Res. Hum. Retroviruses 28 2012 54 75
11. J.-L. Darlix, J.L. Garrido, N. Morellet, Y. Mély, and H. de Rocquigny Properties, functions, and drug targeting of the multifunctional nucleocapsid protein of the human immunodeficiency virus Adv. Pharmacol. 55 2007 299 346
12. D. Muriaux, and J.-L. Darlix Properties and functions of the nucleocapsid protein in virus assembly RNA Biol. 7 2010 744 853
13. U.K. von Schwedler, K.M. Stray, J.E. Garrus, and W.I. Sundquist Functional surfaces of the human immunodeficiency virus type 1 capsid protein J. Virol. 77 2003 5439 5450
14. W.I. Sundquist, and C.P. Hill How to assemble a capsid Cell 131 2007 17 19
15. B.M. Forshey, U. von Schwedler, W.I. Sundquist, and C. Aiken Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication J. Virol. 76 2002 5667 5677
16. B.K. Ganser-Pornillos, U.K. von Schwedler, K.M. Stray, C. Aiken, and W.I. Sundquist Assembly properties of the human immunodeficiency virus type 1 CA protein J. Virol. 78 2004 2545 2552
17. C.T. Lemke, S. Titolo, U. von Schwedler, N. Goudreau, J.-F. Mercier, and E. Wardrop Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein J. Virol. 86 2012 6643 6655
18. L.D. Fader, R. Bethell, P. Bonneau, M. Bös, Y. Bousquet, and M.G. Cordingley Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly Bioorg. Med. Chem. Lett. 21 2011 398 404
19. M. Tremblay, P. Bonneau, Y. Bousquet, P. DeRoy, J. Duan, and M. Duplessis Inhibition of HIV-1 capsid assembly; optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1- yl)-1H-benzimidazole scaffold Bioorg. Med. Chem. Lett. 22 2012 7512 7517
20. Y.M. Ma, and V.M. Vogt Nucleic acid binding-induced Gag dimerization in the assembly of Rous sarcoma virus particles in vitro J. Virol. 78 2004 52 60
21. R.J. Fisher, A. Rein, M. Fivash, M.A. Urbaneja, J.R. Casas-Finet, M. Medaglia, and L.E. Henderson Sequence-specific binding of human immunodeficiency virus type 1 nucleocapsid protein to short oligonucleotides J. Virol. 72 1998 1902 1909
22. C. Vuilleumier, E. Bombarda, N. Morellet, D. Gerard, B.P. Roques, and Y. Mely Nucleic acid sequence discrimination by the HIV-1 nucleocapsid protein NCp7: a fluorescence study Biochemistry 38 1998 16816 16825
23. H. de Rocquigny, V. Shvadchak, S. Avilov, C.Z. Dong, U. Dietrich, J.-L. Darlix, and Y. Mély Targeting the viral nucleocapsid protein in anti-HIV-1 therapy Mini Rev. Med. Chem. 8 2008 24 35
24. D.A. Case, T.A. Darden, T.E. Cheatham III, C.L. Simmerling, J. Wang, and R.E. Duke AMBER 8 2004 University of California San Francisco
25. Y. Duan, C. Wu, S. Chowdhury, M.C. Lee, G. Xiong, and W. Zhang A point-charge force field for molecular mechanics simulations of proteins J. Comput. Chem. 24 2003 1999 2012
26. J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case Development and testing of a general Amber force field J. Comput. Chem. 25 2004 1157 1174
27. A. Jakalian, B.L. Bush, D.B. Jack, and C.I. Bayly Fast, efficient generation of high-quality atomic charges. AM1-BCC model: I Method J. Comput. Chem. 21 2000 132 146
28. 1H NMR EMBO J. 11 1992 3059 3065
29. M.F. Summers, L.E. Henderson, M.R. Chance, J.W. Bess Jr, T.L. South, and P.R. Blake Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact viruses and the solution-state structure of the nucleocapsid protein from HIV-1 Protein Sci. 1 1992 563 574
30. N. Morellet, H. Déméné, V. Teilleux, T. Huynh-Dinh, H. de Rocquigny, M.-C. Fournié-Zaluski, and B.P. Roques Structure of the complex between the HIV-1 nucleocapsid protein NCp7 and the single-stranded pentanucleotide d(ACGCC) J. Mol. Biol. 283 1998 419 434
31. R.N. De Guzman, Z.R. Wu, C.C. Stalling, L. Pappalardo, P.N. Borer, and M.F. Summers Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element Science 279 1998 384 388
32. G.K. Amarasinghe, R.N. De Guzman, R.B. Turner, K.J. Chancellor, Z.R. Wu, and M.F. Summers NMR structure of the HIV-1 nucleocapsid protein bound to stem-loop SL2 of the RNA packaging signal: implications for genome recognition J. Mol. Biol. 301 2000 491 511
33. S. Bourbigot, N. Ramalanjaona, C. Boudier, G.F.J. Salgado, B.P. Roques, and Y. Mély How the HIV-1 nucleocapsid protein binds and destabilises the (-)primer binding site during reverse transcription J. Mol. Biol. 383 2008 1112 1128
34. A. Bazzi, L. Zargarian, F. Chaminade, C. Boudier, H. De Rocquigny, and B. René Structural insights into the cTAR DNA recognition by the HIV-1 nucleocapsid protein: role of sugar deoxyriboses in the binding polarity of NC Nucleic Acids Res. 39 2011 3903 3916
35. G.K. Amarasinghe, J. Zhou, M. Miskimon, K.J. Chancellor, J.A. McDonald, and A.G. Matthews Stem-loop SL4 of the HIV-1 RNA packaging signal exhibits weak affinity for the nucleocapsid protein. Structural studies and implications for genome recognition. J. Mol. Biol. 314 2001 961 970
36. S. Druillennec, and B.P. Roques HIV-1 NCp7 as the target for the design of novel antiviral agents Drug News Perspect. 13 2000 337 349
37. V. Goldschmidt, L.M. Miller Jenkins, H. de Rocquigny, J.-L. Darlix, and Y. Mély The nucleocapsid protein of HIV-1 as a promising therapeutic target for antiviral drugs HIV Ther. 4 2010 179 198
38. L.M. Jenkins, J.C. Byrd, T. Hara, P. Srivastava, S.J. Mazur, and S.J. Stahl Studies on the mechanism of inactivation of the HIV-1 nucleocapsid protein NCp7 with 2-mercaptobenzamide thioesters J. Med. Chem. 48 2005 2847 2858
39. T. Vercruysse, B. Basta, W. Dehaen, N. Humbert, J. Balzarini, and F. Debaene A phenyl-thiadiazolylidene-amine derivative ejects zinc from retroviral nucleocapsid zinc fingers and inactivates HIV virions Retrovirology 9 2012 95
40. J.A. Turpin, M.L. Schito, L.M. Jenkins, J.K. Inman, and E. Appella Topical microbicides: a promising approach for controlling the AIDS pandemic via retroviral zinc finger inhibitors Adv. Pharmacol. 56 2008 229 256
41. G.S. Wallace, C. Cheng-Mayer, M.L. Schito, P. Fletcher, L.M. Miller Jenkins, and R. Hayashi Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection J. Virol. 83 2009 9175 9182
42. S. Druillennec, C.Z. Dong, S. Escaich, N. Gresh, A. Bousseau, B.P. Roques, and M.-C. Fournié-Zaluski A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity Proc. Natl Acad. Sci. USA 96 1999 4886 4891
43. B. Grigorov, A. Bocquin, C. Gabus, S. Avilov, Y. Mély, and A. Agopian Identification of a methylated oligoribonucleotide as a potent inhibitor of HIV-1 reverse transcription complex Nucleic Acids Res. 39 2011 5586 5596
44. L.M. Miller Jenkins, D.E. Ott, R. Hayashi, L.V. Coren, D. Wang, and Q. Xu Small-molecule inactivation of HIV-1 NCp7 by repetitive intracellular acyl transfer Nat. Chem. Biol. 6 2010 887 889
45. Y.Y. Jeong, S.H. Kim, S.I. Jang, and J.C. You Examination of specific binding activity of aptamer RNAs to the HIV-NC by using a cell-based in vivo assay for protein-RNA interaction BMB Rep. 41 2008 511 515
46. S.J. Kim, M.Y. Kim, J.H. Lee, J.C. You, and S. Jeong Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein Biochem. Biophys. Res. Commun. 291 2002 925 931
47. S. Druillennec, H. Meudal, B.P. Roques, and M.-C. Fournié-Zaluski Nucleomimetic strategy for the inhibition of HIV-1 nucleocapsid protein NCp7 activities Bioorg. Med. Chem. Lett. 9 1999 627 632
48. V. Shvadchak, S. Sanglier, S. Rocle, P. Villa, J. Haiech, and M. Hibert Identification by high throughput screening of small compounds inhibiting the nucleic acid destabilization activity of the HIV-1 nucleocapsid protein Biochimie 91 2009 916 923
49. S. Breuer, M.W. Chang, J. Yuan, and B.E. Torbett Identification of HIV-1 inhibitors targeting the nucleocapsid protein J. Med. Chem. 55 2012 4968 4977
50. M. Mori, P. Schult-Dietrich, B. Szafarowicz, N. Humbert, F. Debaene, and S. Sanglier-Cianferani Use of virtual screening for discovering antiretroviral compounds interacting with the HIV-1 nucleocapsid protein Virus Res. 169 2012 377 387
51. 15N protein-based NMR and X-ray crystallography: hit validation of a new benzodiazepine series ChemMedChem 3 2013 405 414
52. M. Sattler, J. Schleucher, and C. Griesinger Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients Prog. Nucl. Magn. Reson. Spectrosc. 34 1999 93 158
53. D. Suarez, E.N. Brothers, and K.M. Merz Jr. Insights into the structure and dynamics of the dinuclear zinc β-lactamase site from Bacteroides fragilis Biochemistry 41 2002 6615 6630